SML0183

EM20-25

≥98% (HPLC)

• Synonym(e): 5-(6-Chloro-2,4-dioxo-1,3,4,10-tetrahydro-2H-9-oxa-1,3-diaza-anthracen-10-yl)-pyrimidine-2,4,6-trione
• Empirische Formel (Hill-System): C₁₅H₉ClN₄O₆
• CAS-Nummer: 141266-44-6
• Molekulargewicht: 376.71
• MDL-Nummer: MFCD00624842
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329825212
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: light yellow to yellow
• Löslichkeit: DMSO: ≥5 mg/mL at ~60 °C
• Lagertemp.: 2-8°C
• SMILES String: Clc1ccc2OC3=C(C(C4C(=O)NC(=O)NC4=O)c2c1)C(=O)NC(=O)N3
• InChI: 1S/C15H9ClN4O6/c16-4-1-2-6-5(3-4)7(8-10(21)17-14(24)18-11(8)22)9-12(23)19-15(25)20-13(9)26-6/h1-3,7-8H,(H2,19,20,23,25)(H2,17,18,21,22,24)
• InChIKey: GGEVZGGAQHNWQN-UHFFFAOYSA-N

Beschreibung

Anwendung

EM20-25 was screened among other anti-cancer drugs to evaluate the effect on mitochondrial membrane potential in human prostate cancer cells and healthy mouse liver tissue.

Biochem./physiol. Wirkung

EM20-25 disrupts the BCL-2/BAX interactions and activates caspase-9 in cells overexpressing BCL-2. It sensitizes the BCL-2 expressing leukemic cells to the effects of chemotherapy involving staurosporine and chlorambucil.

EM20-25 is an analog of HA14-1 that antagonizes the effects of the anti-apoptotic protein BCL-2, and causes opening of the mitochondrial permeability transition pore. Unlike HA14-1, EM20-25 does not effect mitochondrial respiration.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable